Joby Abraham
17 Mar 2023
MaQxan® (204) on Macular Pigment Optical Density (MPOD) and eye stress response through protecting photoreceptor cells from blue light effects
Macular pigment (MP), consisting of lutein (L) and zeaxanthin (Z), is believed to provide retinal protection against photo-oxidative damage. The current study investigates the response to supplemental MaQxan® (204) lutein and zeaxanthin in terms of macular pigment optical density (MPOD).
The aim of this study was to determine the distribution of MaQxan® (204) in the healthy macula and how these variables relate to various demographic factors. 60 subjects were enrolled in the trial as per the inclusion criteria.
Three groups of subjects were created: A, B, and C. All the subjects were given MaQxan® (204) and placebo as per the randomization chart prepared computationally. As the study is double-blinded, subjects getting MaQxan® (204) or placebo were coded.
This three-arm study had A, B, and C groups, where the A group got MaQxan® (204) for the complete 8 months, the B group got MaQxan® (204) for the first 4 months and Placebo for the next 4 months, and the C group got placebo for the first 4 months and MaQxan® (204) for the next 4 months. Macular pigment optical density (OD) at 30 eccentricity at the baseline time point ranged from 0.08 to 1.04, and it was highly connected with better visual performance.
After supplementing MaQxan® (204) after 8 months, the average MPOD (at 30 eccentricity) increased from 0.41 to 0.57. MaQxan® (204), supplementation improved most individuals' visual performance and considerably enhanced MPOD after 4 months of consumption. MaQxan® (204) may be a useful therapeutic agent in managing the protection of photoreceptor cells against diseases and blue light effects.